Dan Samuel Kaufman

USPTO Granted Patents = 9 (Patent Applications = 10)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 2.9

ph-index = 5

Forward Citations = 194(Granted Patents)

Location History:

Madison, WI (US) (2001 - 2003)
Minneapolis, MN (US) (2016)
La Jolla, CA (US) (2020)
Woodbury, MN (US) (2007 - 2024)

Company Filing History:

5 out of 2,310

University of Minnesota

patents

3 out of 4,126

Wisconsin Alumni Research Foundation

patents

1 out of 832,891

Other

patents

Years Active: 2001-2024

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12098182 - Polypeptides, cells, and methods involving engineered CD16 (2024-09-24),

2. 12030953 - Chimeric antigen receptors, compositions, and methods (2024-07-09),

3. 11370825 - Polypeptides, cells, and methods involving engineered CD16 (2022-06-28),

4. 10640570 - Chimeric antigen receptors, compositions, and methods (2020-05-05),

5. 10464989 - Polypeptides, cells, and methods involving engineered CD16 (2019-11-05),

6. 9260696 - Method for developing natural killer cells from stem cells (2016-02-16),

7. 7176023 - Endothelial cells derived from primate embryonic stem cells (2007-02-13),

8. 6613568 - Hematopoietic differentiation of human embryonic stem cells (2003-09-02),

9. 6280718 - Hematopoietic differentiation of human pluripotent embryonic stem cells (2001-08-28),

Title: Dan Samuel Kaufman: Innovator in Immunotherapy

Introduction

Dan Samuel Kaufman is a prominent inventor based in Woodbury, MN (US). He has made significant contributions to the field of immunotherapy, particularly through his innovative work on engineered cells and chimeric antigen receptors. With a total of 9 patents, Kaufman's inventions are paving the way for advancements in cancer treatment and viral infections.

Latest Patents

Kaufman's latest patents include groundbreaking technologies such as modified forms of CD16 and chimeric antigen receptors. The first patent describes a modified form of CD16, which is a genetically-modified cell that exhibits increased anti-tumor and/or anti-viral activity. This is achieved through reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation. The second patent focuses on chimeric antigen receptors designed for expression in Natural Killer (NK) cells. This invention includes pharmaceutical compositions that utilize NK cells modified to express these receptors, enhancing their ability to target and destroy cancer cells.

Career Highlights

Throughout his career, Kaufman has worked with esteemed institutions such as the University of Minnesota and the Wisconsin Alumni Research Foundation. His research has significantly impacted the development of therapies that harness the power of the immune system to combat diseases.

Collaborations

Kaufman has collaborated with notable colleagues, including Bruce Kenneth Walcheck and Jianming Wu. Their combined expertise has contributed to the advancement of innovative solutions in the field of immunotherapy.

Conclusion

Dan Samuel Kaufman is a key figure in the realm of immunotherapy, with a focus on engineered cells and chimeric antigen receptors. His contributions are vital for the future of cancer treatment and viral infection therapies.

This text is generated by artificial intelligence and may not be accurate.